For years, patients with a specific genomic subtype of lung cancer faced a stark choice: intravenous chemotherapy, or an experimental IV antibody that required weekly infusions at a clinic. On Monday, AstraZeneca moved to change that — paying $600 million upfront to acquire worldwide rights to a once-daily oral pill that just beat chemotherapy in a landmark Phase III trial, becoming the first oral monotherapy to do so in this notoriously treatment-resistant cancer subtype, according to the company’s official announcement.

The drug is Zegfrovy (sunvozertinib), developed by Shanghai-based Dizal Pharmaceutical for patients with non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations — a genomic variant that has historically resisted every standard EGFR-targeted pill on the market. AstraZeneca’s total potential outlay reaches $1.5 billion when milestone payments are included, plus tiered royalties on global sales, per the exclusive global license agreement.

Why Every Prior Oral EGFR Drug Failed This Patient Population

To understand why WU-KONG28’s result matters, it helps to understand what makes EGFR exon 20 insertion mutations structurally different from the classical EGFR mutations that drugs like Tagrisso (osimertinib) target effectively.

EGFR — the epidermal growth factor receptor — is a transmembrane protein that, when mutated in lung cancer, fires continuously, driving uncontrolled tumor cell proliferation. In the most common EGFR mutations (exon 19 deletions and the L858R point mutation in exon 21), first- and third-generation TKIs bind readily to the receptor’s ATP-binding pocket and shut down its signaling. In exon 20 insertion mutations, however, the insertion of extra nucleotides after the C-helix of the EGFR kinase domain physically shifts the C-helix and the adjacent P-loop into the drug-binding pocket, creating steric hindrance that dramatically reduces how tightly standard inhibitors can bind while preserving the receptor’s oncogenic activity, as documented in peer-reviewed analyses of EGFR exon 20 resistance mechanisms. That structural difference is why older EGFR TKIs post response rates of just 3–8% in these patients — not because the drugs are weak, but because they cannot reach their target in the modified pocket.

Sunvozertinib was designed specifically to solve this problem. Built on the osimertinib molecular scaffold, it replaces osimertinib’s rigid methylindole group with a more flexible anilinophenyl group — a structural modification that allows the drug to fit inside the sterically restricted pocket that ex20ins-mutated receptors present. Once positioned, its acrylamide warhead forms an irreversible covalent bond with Cys797, a cysteine residue in the kinase domain, permanently blocking the signaling pathway. The result is 1.4 to 9.6 times greater selectivity for the mutant receptor over wild-type EGFR than earlier-generation exon 20 inhibitors — a property that matters clinically because wild-type EGFR inhibition drives the rash and diarrhea that limited the tolerability of earlier attempts in this indication.

WU-KONG28: What the Phase III Trial Showed

The Phase III WU-KONG28 trial enrolled 324 previously untreated patients with locally advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations across 16 countries in Asia, Europe, North America, and South America, according to Dizal’s announcement of the results. Patients were randomized 1:1 to receive either sunvozertinib at 300 mg once daily or standard platinum-doublet chemotherapy (carboplatin plus pemetrexed, followed by pemetrexed maintenance). The primary endpoint was progression-free survival — the time until disease worsened or a patient died — assessed by blinded independent central review.

The results were unambiguous. Sunvozertinib extended median progression-free survival to 10.3 months compared with 7.5 months for chemotherapy — a hazard ratio of 0.65, with a p-value of 0.0008, meaning the probability of the result occurring by chance was less than one in a thousand, as reported in the detailed ASCO Post analysis. The objective response rate by blinded central review was 58.9% for sunvozertinib versus 31.1% for chemotherapy, and the median duration of response was 11.2 months versus 7.1 months, per Dizal’s results announcement. The data were presented as a late-breaking oral session at the 2026 American Society of Clinical Oncology Annual Meeting in May and simultaneously published in The New England Journal of Medicine.

“These results support sunvozertinib as first-line treatment for NSCLC with EGFR exon 20 insertions, with the advantage of a single oral agent administration,” said Dr. John V. Heymach, the endowed chair of thoracic/head and neck medical oncology at MD Anderson Cancer Center in Houston, who presented the findings at ASCO.

The safety profile was consistent with prior studies. The most common grade 3 or higher adverse events were elevated creatine kinase, diarrhea, and anemia — manageable toxicities that fall well below the grade 3–4 adverse event rates that characterized mobocertinib, sunvozertinib’s withdrawn predecessor in this space, per Dizal’s safety data.

Why This Trial Result Carried More Weight Than Usual

The positive WU-KONG28 outcome carries particular significance because of the history of failure in this indication. Takeda’s mobocertinib (Exkivity), the first oral TKI approved for EGFR exon 20 insertion NSCLC, was withdrawn from the US market in October 2023 after its Phase III EXCLAIM-2 confirmatory trial showed no meaningful progression-free survival advantage over chemotherapy — a result so discouraging that potential suitors reportedly held back from sunvozertinib during Dizal’s partner search ahead of the WU-KONG28 readout.

Structurally, mobocertinib shares sunvozertinib’s covalent Cys797 binding approach but lacks the flexible anilinophenyl modification that allows sunvozertinib to access the restricted pocket without triggering significant wild-type EGFR toxicity. The EXCLAIM-2 failure validated the mechanism hypothesis: selectivity matters, and mobocertinib was not selective enough.

WU-KONG28 is the first global randomized Phase III trial to produce a positive result for any oral, chemotherapy-free, single-agent targeted therapy in first-line EGFR exon 20 insertion NSCLC, according to Dizal’s results announcement.

How Sunvozertinib Compares to the Current Standard of Care

The existing FDA-approved first-line option in this setting is Johnson & Johnson’s Rybrevant (amivantamab-vmjw) in combination with carboplatin and pemetrexed — a regimen the FDA approved on March 1, 2024, based on the PAPILLON trial. PAPILLON demonstrated a median progression-free survival of 11.4 months for the amivantamab-chemo combination versus 6.7 months for chemotherapy alone, according to the ASCO Post’s coverage of the approval.

The comparison between PAPILLON and WU-KONG28 is indirect — separate trials in different patient populations — and head-to-head data do not exist. WU-KONG28’s sunvozertinib monotherapy PFS of 10.3 months is numerically shorter than PAPILLON’s amivantamab-plus-chemo PFS of 11.4 months. But there is a structural distinction: amivantamab must be given intravenously, starting weekly for the first month and then every three weeks thereafter — requiring repeated clinic visits and carrying significant infusion-related reaction risk and skin toxicity burden, per the Rybrevant prescribing information. Sunvozertinib is a single tablet taken once daily at home.

The relevant question for patients and oncologists is whether the convenience and tolerability advantage of oral monotherapy outweighs the numerically higher PFS of combination therapy — a question that will likely be answered in practice through patient preference data and eventually in head-to-head studies.

One critical caveat: WU-KONG28’s overall survival data are not yet mature. The trial allowed patients on the chemotherapy arm to cross over to sunvozertinib upon confirmed progression, a design that will dilute the mature OS signal when it becomes available. Whether sunvozertinib translates a PFS benefit into an OS advantage remains to be confirmed.

What Happens If the FDA Approves the First-Line Indication

Dizal filed a Supplemental New Drug Application with the FDA seeking first-line approval for sunvozertinib, supported by WU-KONG28 data. Both the FDA and China’s Center for Drug Evaluation have granted Breakthrough Therapy Designation to sunvozertinib in the first-line EGFR exon 20 insertion setting — a regulatory designation that typically targets a six-month review window and comes with more intensive FDA guidance during the evaluation period, per Targeted Oncology’s coverage of the BTD.

A six-month review from the filing would place a potential FDA decision in late 2026 or early 2027. If approved, Zegfrovy would enter the first-line space as the only oral monotherapy option for this patient population — positioned against the amivantamab-based IV regimen that currently holds the first-line label.

AstraZeneca’s Unusual Position in This Deal

The transaction carries a backstory that most pharmaceutical licensing deals do not. AstraZeneca effectively created Dizal in 2017 by carving out its own Shanghai Innovation Center China into a joint venture, seeding it with staff, research capabilities, and early-stage pipeline candidates — including the preclinical work that eventually became sunvozertinib. Dizal’s CEO, Dr. Xiaolin Zhang, previously led AstraZeneca’s Innovation Center China. AstraZeneca retained a 23.4% equity stake in Dizal — its single largest shareholding, tied with a Chinese state investment fund — but allowed Dizal to take the compound through the expensive and risky years of clinical development, including a successful Phase II data package that earned FDA accelerated approval for the post-platinum setting in July 2025.

AstraZeneca is now paying $600 million upfront — plus up to $900 million in milestones and tiered royalties on global sales — to take back commercial control of the drug it originally seeded, per the exclusive global license agreement.

The deal is part of a broader push by AstraZeneca to access China’s pharmaceutical pipeline. The company has committed $15 billion to expand R&D and manufacturing in China through 2030. In recent weeks it also signed a potential $5.2 billion agreement with CSPC Pharmaceutical and a deal worth up to $2.1 billion for rights to Sino Biopharmaceutical’s COPD drug.

Acquired Resistance: The Remaining Engineering Problem

Like all covalent EGFR inhibitors, sunvozertinib is expected to eventually face acquired resistance. The EGFR C797S mutation — which alters the cysteine residue that sunvozertinib binds irreversibly — has already been identified as a potential on-target resistance mechanism in biomarker studies. C797S is the same resistance pathway seen with osimertinib, and it prevents covalent bond formation, effectively rendering the drug’s warhead inert against the mutated receptor.

Off-target bypass mechanisms — activation of parallel signaling pathways through MET, PI3K/AKT, or BRAF — are anticipated based on the resistance patterns seen with other EGFR TKIs but have not yet been characterized clinically in sunvozertinib-treated patients. These mechanisms are the subject of ongoing translational research, and the post-progression treatment sequence after sunvozertinib failure remains an open clinical question.

The Market These Drugs Compete In

Lung cancer is the leading cause of cancer death globally, responsible for approximately one-fifth of all cancer deaths. NSCLC accounts for 80 to 85 percent of all lung cancer cases, and about 75 percent of NSCLC patients present with advanced disease at diagnosis, according to AstraZeneca’s deal announcement. EGFR mutations occur in roughly 10 to 15 percent of NSCLC patients in the United States and Europe, and 30 to 40 percent in Asia — a geography particularly relevant to a drug whose pivotal trial enrolled 63 percent Asian patients and was co-developed by a Chinese company.

Within the EGFR-mutated subset, exon 20 insertions represent roughly one in four patients with atypical or other EGFR mutations, or about 1 to 2 percent of all NSCLC patients globally, per the AstraZeneca announcement. For AstraZeneca, this subset fills a gap that Tagrisso cannot address: osimertinib’s structure targets classical exon 19 and exon 21 mutations and is largely ineffective against the structurally different exon 20 insertion proteins. Tagrisso generated $7.25 billion in global sales in 2025, anchoring AstraZeneca’s EGFR franchise, per the company’s full-year 2025 results. Zegfrovy, if approved in first-line, would expand that franchise to patients osimertinib cannot reach.

The deal is expected to close in the second half of 2026, pending customary regulatory clearances, and AstraZeneca has stated the transaction will not affect its financial guidance for the year, per the company’s official announcement.

Frequently Asked QuestionsWhat is sunvozertinib (Zegfrovy), and what is it currently approved for?

Sunvozertinib is an oral, once-daily irreversible EGFR tyrosine kinase inhibitor designed to target EGFR exon 20 insertion mutations in non-small cell lung cancer — a genomic variant that resists all standard EGFR-targeted drugs. It received FDA accelerated approval in July 2025 for patients whose disease progressed after platinum-based chemotherapy. Dizal has filed a Supplemental New Drug Application to expand approval to the first-line setting, based on the positive WU-KONG28 Phase III trial results presented at ASCO 2026.

How does sunvozertinib differ from amivantamab (Rybrevant) for EGFR exon 20 lung cancer?

Amivantamab is a bispecific monoclonal antibody that binds to EGFR and MET receptors from outside the cell and must be given intravenously — initially weekly, then every three weeks — in combination with platinum-based chemotherapy. Sunvozertinib is a small-molecule covalent inhibitor taken as a once-daily oral tablet, without chemotherapy. In their respective Phase III trials, amivantamab plus chemotherapy (PAPILLON) showed a median PFS of 11.4 months, while sunvozertinib monotherapy (WU-KONG28) showed 10.3 months — though these were separate trials and no direct comparison exists. The practical difference for patients is oral convenience versus IV-based combination therapy with higher toxicity burden.

Why did the previous oral drug for EGFR exon 20 lung cancer fail where sunvozertinib succeeded?

Mobocertinib (Exkivity), withdrawn from the US market in 2023 after its Phase III trial matched chemotherapy rather than beating it, also bound covalently to Cys797 in the EGFR kinase domain. The structural difference is the molecular group that positions the drug in the binding pocket: mobocertinib lacked the flexible anilinophenyl modification that allows sunvozertinib to fit comfortably inside the sterically restricted ATP-binding pocket created by the C-helix shift characteristic of exon 20 insertions. Sunvozertinib’s greater selectivity for mutant over wild-type EGFR also reduces the toxicity that limited mobocertinib’s dosing.

Will sunvozertinib cure EGFR exon 20 lung cancer?

No EGFR-targeted therapy has cured advanced NSCLC. Sunvozertinib extends the time before disease worsens — median 10.3 months in WU-KONG28 versus 7.5 months for chemotherapy — and produces tumor responses in the majority of patients, but like all covalent EGFR inhibitors it is expected to eventually face acquired resistance. The EGFR C797S mutation has already been identified as a potential on-target resistance mechanism that blocks the covalent bond sunvozertinib depends on. Whether the drug improves overall survival — how long patients live, not just how long before their disease progresses — awaits mature data from the WU-KONG28 trial.